Details for: EIF2B5
Gene ID: 8893
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: EIF2B5
Ensembl ID: ENSG00000145191
Description: eukaryotic translation initiation factor 2B subunit epsilon
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 11.42rCSI 14.66%PRS 69.02
-
CSI 9.32rCSI 14.4%PRS 77.68
-
CSI 7.68rCSI 9.5%PRS 76.49
-
CSI 5.36rCSI 6.53%PRS 85.19
-
CSI 5.17rCSI 4.18%PRS 80.85
-
CSI 4.46rCSI 11.34%PRS 71.93
-
CSI 4.4rCSI 4.24%PRS 77.87
-
CSI 4.18rCSI 3.14%PRS 84.28
-
CSI 3.68rCSI 6.36%PRS 70.1
-
CSI 3.65rCSI 5.61%PRS 68.54
-
CSI 3.58rCSI 2.49%PRS 89.56
-
CSI 3.49rCSI 8.33%PRS 79.05
-
CSI 3.46rCSI 3.19%PRS 80.06
-
CSI 3.43rCSI 2.39%PRS 91.9
-
CSI 3.09rCSI 2.56%PRS 81.21
-
CSI 3.09rCSI 2.88%PRS 79.3
-
CSI 3.05rCSI 4.36%PRS 79.52
-
CSI 2.98rCSI 2.27%PRS 90.5
-
CSI 2.96rCSI 2.45%PRS 79.19
-
CSI 2.93rCSI 2.57%PRS 83.58
-
CSI 2.88rCSI 2.15%PRS 90.61
-
CSI 2.81rCSI 5.06%PRS 72.1
-
CSI 2.77rCSI 4.48%PRS 73.59
-
CSI 2.76rCSI 4.64%PRS 60.56
-
CSI 2.74rCSI 15.72%PRS 82.7
-
CSI 2.72rCSI 3.92%PRS 84.6
-
CSI 2.72rCSI 1.6%PRS 93.11
-
CSI 2.68rCSI 3.15%PRS 80.28
-
CSI 2.64rCSI 5.04%PRS 88.3
-
CSI 2.63rCSI 1.89%PRS 90.75
-
CSI 2.61rCSI 5.96%PRS 79.48
-
CSI 2.58rCSI 3.53%PRS 83.05
-
CSI 2.56rCSI 5.15%PRS 68.72
-
CSI 2.52rCSI 3.05%PRS 59.92
-
CSI 2.51rCSI 2.62%PRS 77.85
-
CSI 2.47rCSI 4.22%PRS 91.08
-
CSI 2.47rCSI 1.66%PRS 90.76
-
CSI 2.46rCSI 2.89%PRS 91.49
-
CSI 2.43rCSI 5.45%PRS 61.43
-
CSI 2.29rCSI 2.25%PRS 91.26
-
CSI 2.28rCSI 1.8%PRS 67.16
-
CSI 2.27rCSI 3.59%PRS 80.29
-
CSI 2.25rCSI 4.21%PRS 66.99
-
CSI 2.25rCSI 3%PRS 85.05
-
CSI 2.23rCSI 1.67%PRS 90.76
-
CSI 2.19rCSI 1.53%PRS 81.99
-
CSI 2.18rCSI 2.77%PRS 83.51
-
CSI 2.15rCSI 1.67%PRS 82.15
-
CSI 2.13rCSI 2.12%PRS 72.37
-
CSI 2.11rCSI 2.27%PRS 79.8
-
CSI 2.09rCSI 3.11%PRS 78.76
-
CSI 2.06rCSI 1.37%PRS 81.46
-
CSI 2.04rCSI 1.62%PRS 94.31
-
CSI 2.02rCSI 5.97%PRS 79.62
-
CSI 1.98rCSI 3.5%PRS 59.83
-
CSI 1.96rCSI 2.99%PRS 82.57
-
CSI 1.95rCSI 7.06%PRS 93.06
-
CSI 1.95rCSI 2.42%PRS 58.47
-
CSI 1.93rCSI 1.57%PRS 77.92
-
CSI 1.89rCSI 2.27%PRS 76.23
-
CSI 1.88rCSI 3.03%PRS 68.66
-
CSI 1.83rCSI 4.18%PRS 72.52
-
CSI 1.81rCSI 3.86%PRS 85.1
-
CSI 1.79rCSI 2.07%PRS 70.8
-
CSI 1.75rCSI 2.39%PRS 70.14
-
CSI 1.74rCSI 2.8%PRS 62.2
-
CSI 1.71rCSI 1.49%PRS 88.09
-
CSI 1.67rCSI 1.5%PRS 76.8
-
CSI 1.65rCSI 1.59%PRS 71.64
-
CSI 1.61rCSI 2.11%PRS 88.96
-
CSI 1.59rCSI 1.67%PRS 76.05
-
CSI 1.58rCSI 3.74%PRS 79.26
-
CSI 1.57rCSI 1.32%PRS 81.67
-
CSI 1.56rCSI 2.29%PRS 83.38
-
CSI 1.52rCSI 2.08%PRS 81.18
-
CSI 1.51rCSI 2.31%PRS 75.58
-
CSI 1.51rCSI 6.02%PRS 86.28
-
CSI 1.5rCSI 1.32%PRS 67.63
-
CSI 1.47rCSI 1.13%PRS 81.37
-
CSI 1.47rCSI 1.31%PRS 76.29
-
CSI 1.42rCSI 3.13%PRS 82.31
-
CSI 1.4rCSI 1.67%PRS 60.57
-
CSI 1.38rCSI 1.89%PRS 78.54
-
CSI 1.35rCSI 1.17%PRS 82.66
-
CSI 1.31rCSI 1.85%PRS 78.29
-
CSI 1.27rCSI 1.96%PRS 87.02
-
CSI 1.27rCSI 2.26%PRS 48.27
-
CSI 1.24rCSI 3.22%PRS 77.57
-
CSI 1.23rCSI 6.17%PRS 89.75
-
CSI 1.22rCSI 2.7%PRS 77.98
-
CSI 1.18rCSI 1.52%PRS 61.64
-
CSI 1.15rCSI 1.53%PRS 84.27
-
CSI 1.09rCSI 1.6%PRS 73.09
-
CSI 1.02rCSI 3.85%PRS 61.53
-
CSI 0.96rCSI 3.01%PRS 62.2
-
CSI 0.86rCSI 1.18%PRS 45.55
-
CSI 0.83rCSI 2.02%PRS 58.57
-
CSI 0.72rCSI 4.06%PRS 64.67
-
CSI 0.71rCSI 4.45%PRS 70.38
-
CSI 0.65rCSI 1.43%PRS 64.45
-
CSI 0.4rCSI 2.4%PRS 84.1%
-
CSI 0.5rCSI 1.9%PRS 61.0%
-
CSI 0.6rCSI 2.4%PRS 87.2%
-
CSI 0.6rCSI 2.0%PRS 64.6%
-
CSI 0.6rCSI 2.3%PRS 58.5%
-
CSI 0.6rCSI 2.9%PRS 79.2%
-
CSI 0.7rCSI 1.4%PRS 64.5%
-
CSI 0.7rCSI 4.5%PRS 70.4%
-
CSI 0.7rCSI 4.1%PRS 64.7%
-
CSI 0.8rCSI 2.0%PRS 58.6%
-
CSI 0.9rCSI 1.2%PRS 45.6%
-
CSI 1.0rCSI 3.0%PRS 62.2%
-
CSI 1.0rCSI 3.9%PRS 61.5%
-
CSI 1.1rCSI 1.6%PRS 73.1%
-
CSI 1.2rCSI 1.5%PRS 84.3%
-
CSI 1.2rCSI 1.5%PRS 61.6%
-
CSI 1.2rCSI 2.7%PRS 78.0%
-
CSI 1.2rCSI 6.2%PRS 89.8%
-
CSI 1.2rCSI 3.2%PRS 77.6%
-
CSI 1.3rCSI 2.3%PRS 48.3%
-
CSI 1.3rCSI 2.0%PRS 87.0%
-
CSI 1.3rCSI 1.9%PRS 78.3%
-
CSI 1.4rCSI 1.2%PRS 82.7%
-
CSI 1.4rCSI 1.9%PRS 78.5%
-
CSI 1.4rCSI 1.7%PRS 60.6%
-
CSI 1.4rCSI 3.1%PRS 82.3%
-
CSI 1.5rCSI 1.3%PRS 76.3%
-
CSI 1.5rCSI 1.1%PRS 81.4%
-
CSI 1.5rCSI 1.3%PRS 67.6%
-
CSI 1.5rCSI 6.0%PRS 86.3%
-
CSI 1.5rCSI 2.3%PRS 75.6%
-
CSI 1.5rCSI 2.1%PRS 81.2%
-
CSI 1.6rCSI 2.3%PRS 83.4%
-
CSI 1.6rCSI 1.3%PRS 81.7%
-
CSI 1.6rCSI 3.7%PRS 79.3%
-
CSI 1.6rCSI 1.7%PRS 76.1%
-
CSI 1.6rCSI 2.1%PRS 89.0%
-
CSI 1.7rCSI 1.6%PRS 71.6%
-
CSI 1.7rCSI 1.5%PRS 76.8%
-
CSI 1.7rCSI 1.5%PRS 88.1%
-
CSI 1.7rCSI 2.8%PRS 62.2%
-
CSI 1.8rCSI 2.4%PRS 70.1%
-
CSI 1.8rCSI 2.1%PRS 70.8%
-
CSI 1.8rCSI 3.9%PRS 85.1%
-
CSI 1.8rCSI 4.2%PRS 72.5%
-
CSI 1.9rCSI 3.0%PRS 68.7%
-
CSI 1.9rCSI 2.3%PRS 76.2%
-
CSI 1.9rCSI 1.6%PRS 77.9%
-
CSI 2.0rCSI 2.4%PRS 58.5%
-
CSI 2.0rCSI 7.1%PRS 93.1%
-
CSI 2.0rCSI 3.0%PRS 82.6%
-
CSI 2.0rCSI 3.5%PRS 59.8%
-
CSI 2.0rCSI 6.0%PRS 79.6%
-
CSI 2.0rCSI 1.6%PRS 94.3%
-
CSI 2.1rCSI 1.4%PRS 81.5%
-
CSI 2.1rCSI 3.1%PRS 78.8%
-
CSI 2.1rCSI 2.3%PRS 79.8%
-
CSI 2.1rCSI 2.1%PRS 72.4%
-
CSI 2.2rCSI 1.7%PRS 82.2%
-
CSI 2.2rCSI 2.8%PRS 83.5%
-
CSI 2.2rCSI 1.5%PRS 82.0%
-
CSI 2.2rCSI 1.7%PRS 90.8%
-
CSI 2.3rCSI 3.0%PRS 85.1%
-
CSI 2.3rCSI 4.2%PRS 67.0%
-
CSI 2.3rCSI 3.6%PRS 80.3%
-
CSI 2.3rCSI 1.8%PRS 67.2%
-
CSI 2.3rCSI 2.3%PRS 91.3%
-
CSI 2.4rCSI 5.5%PRS 61.4%
-
CSI 2.5rCSI 2.9%PRS 91.5%
-
CSI 2.5rCSI 1.7%PRS 90.8%
-
CSI 2.5rCSI 4.2%PRS 91.1%
-
CSI 2.5rCSI 2.6%PRS 77.9%
-
CSI 2.5rCSI 3.1%PRS 59.9%
-
CSI 2.6rCSI 5.2%PRS 68.7%
-
CSI 2.6rCSI 3.5%PRS 83.1%
-
CSI 2.6rCSI 6.0%PRS 79.5%
-
CSI 2.6rCSI 1.9%PRS 90.8%
-
CSI 2.6rCSI 5.0%PRS 88.3%
-
CSI 2.7rCSI 3.2%PRS 80.3%
-
CSI 2.7rCSI 1.6%PRS 93.1%
-
CSI 2.7rCSI 3.9%PRS 84.6%
-
CSI 2.7rCSI 15.7%PRS 82.7%
-
CSI 2.8rCSI 4.6%PRS 60.6%
-
CSI 2.8rCSI 4.5%PRS 73.6%
-
CSI 2.8rCSI 5.1%PRS 72.1%
-
CSI 2.9rCSI 2.2%PRS 90.6%
-
CSI 2.9rCSI 2.6%PRS 83.6%
-
CSI 3.0rCSI 2.5%PRS 79.2%
-
CSI 3.0rCSI 2.3%PRS 90.5%
-
CSI 3.1rCSI 4.4%PRS 79.5%
-
CSI 3.1rCSI 2.9%PRS 79.3%
-
CSI 3.1rCSI 2.6%PRS 81.2%
-
CSI 3.4rCSI 2.4%PRS 91.9%
-
CSI 3.5rCSI 3.2%PRS 80.1%
-
CSI 3.5rCSI 8.3%PRS 79.1%
-
CSI 3.6rCSI 2.5%PRS 89.6%
-
CSI 3.7rCSI 5.6%PRS 68.5%
-
CSI 3.7rCSI 6.4%PRS 70.1%
-
CSI 4.2rCSI 3.1%PRS 84.3%
-
CSI 4.4rCSI 4.2%PRS 77.9%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 2036258265
Symbol: EI2BE_HUMAN
Name: Translation initiation factor eIF2B subunit epsilon
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 16641997
Title: The DNA sequence, annotation and analysis of human chromosome 3.
PubMed ID: 16641997
DOI: 10.1038/nature04728
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 8688466
Title: Cloning and characterization of cDNAs encoding the epsilon-subunit of eukaryotic initiation factor-2B from rabbit and human.
PubMed ID: 8688466
PubMed ID: 8397507
Title: Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B.
PubMed ID: 8397507
DOI: 10.1042/bj2940625
PubMed ID: 18088087
PubMed ID: 18691976
Title: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
PubMed ID: 18691976
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19736320
PubMed ID: 19690332
Title: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
PubMed ID: 19690332
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 21406692
Title: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
PubMed ID: 21406692
PubMed ID: 22223895
Title: Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.
PubMed ID: 22223895
PubMed ID: 22814378
Title: N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.
PubMed ID: 22814378
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 25858979
Title: Stress responses. Mutations in a translation initiation factor identify the target of a memory-enhancing compound.
PubMed ID: 25858979
PubMed ID: 27023709
Title: Expression, purification, and crystallization of Schizosaccharomyces pombe eIF2B.
PubMed ID: 27023709
PubMed ID: 31048492
Title: Structural basis for eIF2B inhibition in integrated stress response.
PubMed ID: 31048492
PubMed ID: 11704758
Title: Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter.
PubMed ID: 11704758
DOI: 10.1038/ng764
PubMed ID: 12325082
Title: Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus.
PubMed ID: 12325082
DOI: 10.1002/ana.10339
PubMed ID: 12707859
Title: Ovarian failure related to eukaryotic initiation factor 2B mutations.
PubMed ID: 12707859
DOI: 10.1086/375404
PubMed ID: 15776425
Title: Identification of ten novel mutations in patients with eIF2B-related disorders.
PubMed ID: 15776425
DOI: 10.1002/humu.9325
PubMed ID: 19158808
Title: Identification of novel EIF2B mutations in Chinese patients with vanishing white matter disease.
PubMed ID: 19158808
DOI: 10.1038/jhg.2008.10
PubMed ID: 21484434
Title: Adult-onset leukoencephalopathies with vanishing white matter with novel missense mutations in EIF2B2, EIF2B3, and EIF2B5.
PubMed ID: 21484434
Sequence Information:
- Length: 721
- Mass: 80380
- Checksum: 08B39D3A5EE7D905
- Sequence:
MAAPVVAPPG VVVSRANKRS GAGPGGSGGG GARGAEEEPP PPLQAVLVAD SFDRRFFPIS KDQPRVLLPL ANVALIDYTL EFLTATGVQE TFVFCCWKAA QIKEHLLKSK WCRPTSLNVV RIITSELYRS LGDVLRDVDA KALVRSDFLL VYGDVISNIN ITRALEEHRL RRKLEKNVSV MTMIFKESSP SHPTRCHEDN VVVAVDSTTN RVLHFQKTQG LRRFAFPLSL FQGSSDGVEV RYDLLDCHIS ICSPQVAQLF TDNFDYQTRD DFVRGLLVNE EILGNQIHMH VTAKEYGARV SNLHMYSAVC ADVIRRWVYP LTPEANFTDS TTQSCTHSRH NIYRGPEVSL GHGSILEENV LLGSGTVIGS NCFITNSVIG PGCHIGDNVV LDQTYLWQGV RVAAGAQIHQ SLLCDNAEVK ERVTLKPRSV LTSQVVVGPN ITLPEGSVIS LHPPDAEEDE DDGEFSDDSG ADQEKDKVKM KGYNPAEVGA AGKGYLWKAA GMNMEEEEEL QQNLWGLKIN MEEESESESE QSMDSEEPDS RGGSPQMDDI KVFQNEVLGT LQRGKEENIS CDNLVLEINS LKYAYNISLK EVMQVLSHVV LEFPLQQMDS PLDSSRYCAL LLPLLKAWSP VFRNYIKRAA DHLEALAAIE DFFLEHEALG ISMAKVLMAF YQLEILAEET ILSWFSQRDT TDKGQQLRKN QQLQRFIQWL KEAEEESSED D